In addition to non-steroidal mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists, used for select subpopulations with diabetic kidney disease, are the mainstay medical therapy for chronic kidney disease with the aim of improving long-term hard renal outcomes [47,48]. Here, NR3C2 is linked to diabetic kidney disease.